BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 19442037)

  • 1. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs.
    Ieiri I; Higuchi S; Sugiyama Y
    Expert Opin Drug Metab Toxicol; 2009 Jul; 5(7):703-29. PubMed ID: 19442037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins.
    Hua WJ; Hua WX; Fang HJ
    Cardiovasc Ther; 2012 Oct; 30(5):e234-41. PubMed ID: 21884024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
    Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
    Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein.
    Matsushima S; Maeda K; Kondo C; Hirano M; Sasaki M; Suzuki H; Sugiyama Y
    J Pharmacol Exp Ther; 2005 Sep; 314(3):1059-67. PubMed ID: 15901800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport.
    Kindla J; Müller F; Mieth M; Fromm MF; König J
    Drug Metab Dispos; 2011 Jun; 39(6):1047-53. PubMed ID: 21389119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ethnic variability in the plasma exposures of OATP1B1 substrates such as HMG-CoA reductase inhibitors: a kinetic consideration of its mechanism.
    Tomita Y; Maeda K; Sugiyama Y
    Clin Pharmacol Ther; 2013 Jul; 94(1):37-51. PubMed ID: 23443754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of organic anion-transporting polypeptide 1B1- and 1B3-mediated hepatic uptake of statins based on transporter protein expression and activity data.
    Kunze A; Huwyler J; Camenisch G; Poller B
    Drug Metab Dispos; 2014 Sep; 42(9):1514-21. PubMed ID: 24989890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
    Kulmatycki K; Hanna I; Meyers D; Salunke A; Movva A; Majumdar T; Natrillo A; Vapurcuyan A; Rebello S; Sunkara G; Chen J
    Int J Clin Pharmacol Ther; 2015 May; 53(5):345-55. PubMed ID: 25740267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase.
    Fujino H; Saito T; Ogawa S; Kojima J
    J Pharm Pharmacol; 2005 Oct; 57(10):1305-11. PubMed ID: 16259759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption.
    Shitara Y; Maeda K; Ikejiri K; Yoshida K; Horie T; Sugiyama Y
    Biopharm Drug Dispos; 2013 Jan; 34(1):45-78. PubMed ID: 23115084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
    Elsby R; Martin P; Surry D; Sharma P; Fenner K
    Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans.
    Yamashiro W; Maeda K; Hirouchi M; Adachi Y; Hu Z; Sugiyama Y
    Drug Metab Dispos; 2006 Jul; 34(7):1247-54. PubMed ID: 16624871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transporter studies with the 3-O-sulfate conjugate of 17alpha-ethinylestradiol: assessment of human liver drug transporters.
    Han YH; Busler D; Hong Y; Tian Y; Chen C; Rodrigues AD
    Drug Metab Dispos; 2010 Jul; 38(7):1072-82. PubMed ID: 20360302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of transporters in the disposition of the selective phosphodiesterase-4 inhibitor (+)-2-[4-({[2-(benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid in rat and human.
    Kalgutkar AS; Feng B; Nguyen HT; Frederick KS; Campbell SD; Hatch HL; Bi YA; Kazolias DC; Davidson RE; Mireles RJ; Duignan DB; Choo EF; Zhao SX
    Drug Metab Dispos; 2007 Nov; 35(11):2111-8. PubMed ID: 17686907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans.
    Kivistö KT; Niemi M
    Pharm Res; 2007 Feb; 24(2):239-47. PubMed ID: 17177112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of OATP transporters on pharmacokinetics.
    Kalliokoski A; Niemi M
    Br J Pharmacol; 2009 Oct; 158(3):693-705. PubMed ID: 19785645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of organic anion transporting polypeptide 1B1 and 1B3 humanized mice as a translational model to study the pharmacokinetics of statins.
    Salphati L; Chu X; Chen L; Prasad B; Dallas S; Evers R; Mamaril-Fishman D; Geier EG; Kehler J; Kunta J; Mezler M; Laplanche L; Pang J; Rode A; Soars MG; Unadkat JD; van Waterschoot RA; Yabut J; Schinkel AH; Scheer N
    Drug Metab Dispos; 2014 Aug; 42(8):1301-13. PubMed ID: 24855184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins.
    Generaux GT; Bonomo FM; Johnson M; Doan KM
    Xenobiotica; 2011 Aug; 41(8):639-51. PubMed ID: 21425956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin.
    Custodio JM; Wang H; Hao J; Lepist EI; Ray AS; Andrews J; Ling KH; Cheng A; Kearney BP; Ramanathan S
    J Clin Pharmacol; 2014 Jun; 54(6):649-56. PubMed ID: 24375014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide.
    Ishiguro N; Maeda K; Saito A; Kishimoto W; Matsushima S; Ebner T; Roth W; Igarashi T; Sugiyama Y
    Drug Metab Dispos; 2008 Apr; 36(4):796-805. PubMed ID: 18180273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.